<DOC>
	<DOCNO>NCT00363467</DOCNO>
	<brief_summary>During pre-transplantation phase ( follow completion consolidation chemotherapy ) , patient begin receive G-CSF 10 mcg/kg twice daily ; leukapheresis also give target goal recipient body weight obtain , maximum 5 day . Conditioning/Preparative therapy follow PBSC collection 30 day Busulfan IV daily x 4 day ; subsequent dos adjust base pharmacokinetic ( plasma level ) monitoring . Following 1 day rest , stem cell reinfusion begin supportive care . During follow-up , patient monitor 730 day .</brief_summary>
	<brief_title>Busulfan Monotherapy Conditioning Autologous Hematopoietic Progenitor Cell Transplantation</brief_title>
	<detailed_description>1 . Pre- Transplantation Phase - 1 . Twenty-four 48 hour follow completion consolidation chemotherapy , patient begin receive G-CSF 10 mcg/kg twice daily subcutaneously . Alternatively , patient may receive G-CSF alone ( dose ) mobilization therapy . 2 . Leukapheresis begin day 4 G-CSF administration proceed accord institutional guideline . Leukapheresis continue target goal recipient body weight obtain , maximum 5 day . A minimum recipient body weight require proceed transplantation . 2 . Transplantation Phase a. Conditioning/Preparative therapy - 30 day follow PBSC collection , patient begin condition therapy Busulfan IV daily x 4 day ( transplantation day -5 , -4 , -3 , -2 ) . The day -5 -4 dose 130mg/m2 ; subsequent dos adjust base pharmacokinetic monitoring . - Busulfan plasma level monitoring , collect around first dose busulfan b . Stem cell reinfusion - follow 1 day rest , previously collect autologous peripheral blood stem cell infuse . - The administration supportive measure ( e.g . intravenous fluid , antihistamine ) stem cell reinfusion perform accord institutional guideline . 3 . Supportive care 1 . Antibiotic prophylaxis- accord hospital/institutional guideline , discretion treat physician . 2 . Growth factor support 3 . Transfusion support 4 . Prophylaxis busulfan-induced seizure 4 . During follow-up , patient see least weekly first month periodically 730 day posttransplant . The following medical procedure do : - Medical history physical exam ( include concurrent med , vital sign , performance status weight ) - Standard labs - Bone marrow aspirate biopsy</detailed_description>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Patients must histologically confirm diagnosis AML , 1st complete remission , pathologic review H. Lee Moffitt Cancer Center Research Institute . Any induction/consolidation regimen permit . General 1 . Age 5674 2 . Able give inform consent 3 . Hepatic renal function : normal bilirubin , AST ALT less equal 2x normal limit , serum creatinine less equal 1.5x normal 4 . Left ventricular ejection fraction ( LVEF ) must normal range 5 . FEV1 AND DLCO great equal 50 % predict ( planned time transplantation ) 6 . ECOG PS less equal 2 ( plan time transplantation ) Disease Specific 1 . Adverserisk karyotype ( del 5/5q , 7/7q , 3q , great equal 3 abnormality ) : 2 . Intermediaterisk karyotype [ 46 XY , +8 , Y , +6 , isolate ( &lt; 3 total ) nonrandom abnormality include adverserisk category favorablerisk category ] AML arise antecedent hematologic disorder ( e.g . MDS ) Secondary AML ( tAML ) Acute Promyelocytic Leukemia ( FAB M3 ) subtype Presence ( 8 ; 21 ) translocation inversion 16/t ( 16 ; 16 ) cytogenetic phenotype ( i.e . favorablerisk AML ) Eligible willing undergo matchedsibling allogeneic transplantation Greater 2 induction regimen require achieve complete remission Duration &gt; 8 week completion induction chemotherapy initiation consolidation chemotherapy No prior malignancy allow , except adequately treat basal cell ( squamous cell ) skin cancer , situ cervical cancer , cancer patient diseasefree least 5 year . Prior extensive radiation therapy ( &gt; 25 % bone marrow reserve ) Concomitant radiation therapy , chemotherapy , immunotherapy Intrinsic impair organ function ( state ) Active infection Positive serum pregnancy test woman yet reach menopause ( menstrual period &gt; 12 month undergone tubal ligation complete hysterectomy . Women breastfeed Positive HIV test Presence CNS leukemia Uncontrolled insulindependent diabetes mellitus uncompensated major thyroid adrenal gland dysfunction Physical psychiatric condition estimation PI designee place patient highrisk toxicity noncompliance</criteria>
	<gender>All</gender>
	<minimum_age>56 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Busulfan</keyword>
	<keyword>Acute myeloid leukemia ( AML )</keyword>
	<keyword>Hematopoietic Stem Cell Transplantation ( HSCT )</keyword>
	<keyword>Dendritic cell</keyword>
	<keyword>Bone marrow transplantation</keyword>
	<keyword>PBSC mobilization</keyword>
	<keyword>Autologous stem cell</keyword>
</DOC>